Journal of the National Cancer Institute Advance Access originally published online on June 24, 2008
JNCI Journal of the National Cancer Institute 2008 100(13):916-917; doi:10.1093/jnci/djn228
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
Revised Guidelines Signal That Gene Expression Profiles Are Coming of Age
| The first 10% of the full text of this article appears below. |
When the National Comprehensive Cancer Network (NCCN), a consortium of 21 comprehensive cancer centers, released its most recent breast cancer treatment guidelines in January, they included for the first time the option to use gene expression profiles in the treatment decision-making process.
For many of those who watch the field closely, this addition was a milestone for the burgeoning discipline of molecular diagnostics and a sign of changing times in the practice of medicine.
"This reflects what has occurred in clinical practice," said Eric Winer, M.D., director of the breast oncology center at Dana-Farber Cancer Institute in Boston and a member of the NCCN expert panel charged with reviewing and updating the guidelines. "Gene expression profiles have the potential
Controversy Remains
In Practice